Has William Mecca, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,739 in general payments to William Mecca, MD across 85 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean William Mecca, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about William Mecca, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

William Mecca, MD

Interventional Cardiology · Erie, PANPI 1730167487

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 85 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Medtronic accounts for 70.7% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2023 at $687 and has fallen 83.5% since, to $114 in 2025. That places this record below the midpoint for interventional cardiology clinicians in PA, where the typical reported total is $6,486.

$2,739in general payments, 2019–2025

Across 85 payments — averaging $32.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$2K
Boston Scientific$385
Abiomed$134
Inari Medical, Inc.$126
EKOS Corporation$32
Cordis US CORP.$27
plus $98 from 6 others

$82in research payments, 2019–2025

Across 2 payments — averaging $40.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Amgen$82

What the payments were for

Food & beverage$2,739100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic(2 entities)	49	$1,937
Boston Scientific	21	$385
Abiomed	3	$134
Inari Medical, Inc.	2	$126
EKOS Corporation	2	$32
Cordis US CORP.	1	$27
Cardinal Health 200 LLC	2	$27
Philips North America LLC	1	$23
Amgen	1	$15
Amarin Pharma, Inc.	1	$13
W. L. Gore & Associates, Inc.	1	$11
Vasorum USA Inc.	1	$9

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

RESOLUTE ONYX$138

How this compares

$2,739 in reported general payments places this provider in the 20th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$6,560

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EntrestoSacubitril/Valsartan	20	$29,933
EliquisApixaban	23	$27,013
Repatha SureclickEvolocumab	14	$14,126
FarxigaDapagliflozin Propanediol	18	$13,750
JardianceEmpagliflozin	14	$9,200
Repatha SyringeEvolocumab	13	$6,990
Ranolazine ErRanolazine	53	$3,734
Metoprolol Succinate	126	$1,654
Rosuvastatin Calcium	66	$1,398
Enalapril Maleate	31	$783
Ezetimibe	54	$696
Atorvastatin Calcium	62	$672
Isosorbide Mononitrate ErIsosorbide Mononitrate	57	$376
Metoprolol Tartrate	39	$283
Amlodipine Besylate	35	$239

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Erie

Matthew BeckerErie$1M
Orestis PappasErie$259K
Nishant SethiScranton$1.3M
William GrayWynnewood$753K
Jon GeorgePhiladelphia$637K
Shailendra SinghAllentown$470K
Sanjog KalraPhiladelphia$444K
James HarveyChambersburg$442K
Taisei KobayashiPhiladelphia$384K
Antonis PratsosBroomall$377K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →